ZETIA

This brand name is authorized in United States. It is also authorized in Brazil, Italy, Japan.

Active ingredients

The drug ZETIA contains one active pharmaceutical ingredient (API):

1	Ezetimibe UNII EOR26LQQ24 - EZETIMIBE
	Ezetimibe is in a new class of lipid-lowering compounds that selectively inhibit the intestinal absorption of cholesterol. The molecular target of ezetimibe is the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is responsible for the intestinal uptake of cholesterol.
	Read more about Ezetimibe

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ZETIA Tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C10AX09	Ezetimibe	C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AX Other lipid modifying agents
Discover more medicines within C10AX09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	527314100015503, 527315120017317, 527315120017417
IT	Agenzia del Farmaco	036017147
JP	医薬品医療機器総合機構	2189018F1027
US	FDA, National Drug Code	66582-414